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Abstract: Background: Basal cell carcinomas (BCCs) exhibit aberrant activation of the hedgehog path-
way. Sonidegib is a hedgehog pathway inhibitor approved for the treatment of locally advanced BCC
(laBCC) and metastatic BCC (mBCC) based on primary results of the BOLT study [Basal Cell Carci-
noma Outcomes with LDE225 (sonidegib) Treatment]. Objectives: This is the final 42-month analysis of
the BOLT study, evaluating the efficacy and safety of sonidegib. Methods: Adults with no prior hedgehog
pathway inhibitor therapy were randomized in a 1 : 2 ratio to sonidegib 200 mg or 800 mg once daily.
Treatment continued for up to 42 months or until disease progression, unacceptable toxicity, death, study
termination or withdrawal of consent. The primary efficacy end point was the objective response rate
(ORR) by central review, assessed at baseline; weeks 5, 9 and 17; then subsequently every 8 or 12 weeks
during years 1 or 2, respectively. Safety end points included adverse event monitoring and reporting.
Results: The study enrolled 230 patients, 79 and 151 in the 200-mg and 800-mg groups, respectively, of
whom 8% and 3.3% remained on treatment by the 42-month cutoff, respectively. The ORRs by central
review were 56% [95% confidence interval (CI) 43-68] for laBCC and 8% (95% CI 0·2-36) for mBCC in
the 200-mg group and 46·1% (95% CI 37·2-55·1) for laBCC and 17% (95% CI 5-39) for mBCC in the
800-mg group. No new safety concerns emerged. Conclusions: Sonidegib demonstrated sustained efficacy
and a manageable safety profile. The final BOLT results support sonidegib as a viable treatment option
for laBCC and mBCC. What’s already known about this topic? Basal cell carcinoma (BCC) is usually
treatable with surgery or radiation therapy, but there are limited treatment options for patients with
advanced BCC. Sonidegib, a hedgehog pathway inhibitor approved for the treatment of advanced BCC,
demonstrated clinically relevant efficacy and manageable safety in prior analyses of the phase II random-
ized, double-blind BOLT study [Basal Cell Carcinoma Outcomes with LDE225 (sonidegib) Treatment].
What does this study add? This final 42-month analysis of BOLT is the longest follow-up available for a
hedgehog pathway inhibitor. Clinically relevant efficacy results were sustained from prior analyses, with
objective response rates by central review of the approved 200-mg daily dose of 56% in locally advanced
BCC and 8% in metastatic BCC. No new safety concerns were raised. The results confirmed sonidegib
as a viable long-term treatment option for patients with advanced BCC.
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Summary
Background Basal cell carcinomas (BCCs) exhibit aberrant activation of the hedge-
hog pathway. Sonidegib is a hedgehog pathway inhibitor approved for the treat-
ment of locally advanced BCC (laBCC) and metastatic BCC (mBCC) based on
primary results of the BOLT study [Basal Cell Carcinoma Outcomes with LDE225
(sonidegib) Treatment].
Objectives This is the final 42-month analysis of the BOLT study, evaluating the
efficacy and safety of sonidegib.
Methods Adults with no prior hedgehog pathway inhibitor therapy were randomized
in a 1 : 2 ratio to sonidegib 200 mg or 800 mg once daily. Treatment continued
for up to 42 months or until disease progression, unacceptable toxicity, death,
study termination or withdrawal of consent. The primary efficacy end point was
the objective response rate (ORR) by central review, assessed at baseline; weeks 5,
9 and 17; then subsequently every 8 or 12 weeks during years 1 or 2, respectively.
Safety end points included adverse event monitoring and reporting.
Results The study enrolled 230 patients, 79 and 151 in the 200-mg and 800-mg
groups, respectively, of whom 8% and 3.3% remained on treatment by the 42-
month cutoff, respectively. The ORRs by central review were 56% [95% confidence
interval (CI) 43–68] for laBCC and 8% (95% CI 02–36) for mBCC in the 200-mg group
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DOI 10.1111/bjd.18552 and 461% (95% CI 372–551) for laBCC and 17% (95% CI 5–39) for mBCC in the
800-mg group. No new safety concerns emerged.
Conclusions Sonidegib demonstrated sustained efficacy and a manageable safety
profile. The final BOLT results support sonidegib as a viable treatment option for
laBCC and mBCC.
What’s already known about this topic?
• Basal cell carcinoma (BCC) is usually treatable with surgery or radiation therapy,
but there are limited treatment options for patients with advanced BCC.
• Sonidegib, a hedgehog pathway inhibitor approved for the treatment of advanced
BCC, demonstrated clinically relevant efficacy and manageable safety in prior analy-
ses of the phase II randomized, double-blind BOLT study [Basal Cell Carcinoma
Outcomes with LDE225 (sonidegib) Treatment].
What does this study add?
• This final 42-month analysis of BOLT is the longest follow-up available for a
hedgehog pathway inhibitor.
• Clinically relevant efficacy results were sustained from prior analyses, with objec-
tive response rates by central review of the approved 200-mg daily dose of 56% in
locally advanced BCC and 8% in metastatic BCC.
• No new safety concerns were raised.
• The results confirmed sonidegib as a viable long-term treatment option for patients
with advanced BCC.
The incidence of basal cell carcinoma (BCC) is increasing
worldwide by approximately 1% annually.1,2 For nonadvanced
BCC, primary treatment options include surgical excision,
Mohs micrographic surgery, cryotherapy and radiation ther-
apy.3 In a subset of cases, BCCs can become excessively inva-
sive or destructive; these are known as advanced BCCs and are
defined as BCCs in which current treatment modalities are
contraindicated, potentially because of clinical or patient-
driven factors.4,5 Complex cases of BCC include locally
advanced BCC (laBCC)—in which significant tissue invasion of
the tumour can result in considerable deformity and surgical
excision is unacceptable—and metastatic BCC (mBCC), whose
prognosis is poor, with high morbidity and mortality.5 Inhibi-
tion of the hedgehog signalling pathway is among the few
treatment options available for patients with advanced BCC.
The hedgehog pathway is a key regulator of cell growth
and differentiation during embryonic development but is
mostly silenced in adults, with only limited activity in some
processes, including hair growth and maintenance of taste.6–8
BCCs have been found to carry mutations resulting in aberrant
activation of hedgehog signalling, primarily in the human
homologue of Drosophila patched (PTCH1).6,9–11 Mutations in
the human homologues of smoothened (SMO) and suppressor
of fused (SUFU) have also been found.9–11
Sonidegib (Odomzo; Sun Pharmaceutical Industries, Inc.;
Cranbury, NJ, U.S.A.) is a hedgehog pathway inhibitor (HPI)
selectively targeting smoothened, which is approved in the
U.S.A., European Union, Switzerland and Australia for the
treatment of adult patients with laBCC that has recurred fol-
lowing surgery or radiation therapy, or those who are not
candidates for surgery or radiation therapy.12–15 In Switzer-
land and Australia, sonidegib is also approved for the treat-
ment of mBCC.14,15
A phase I dose escalation study of sonidegib in 103 patients
with advanced solid tumours, including 16 with BCC, found 800
mg to be the maximum tolerated once-daily dose.16 The median
times to reach maximum plasma concentration after administra-
tion were 2 h and 4 h for patients receiving 200 mg and 800 mg
once daily, respectively. Plasma exposure after single-dose admin-
istration increased proportionally with doses ≤ 400 mg once daily
and less than proportionally for doses > 400 mg once daily.16
Approval of sonidegib was based on results of the pivotal
phase II BOLT trial [Basal Cell Carcinoma Outcomes with
LDE225 (sonidegib) Treatment; NCT01327053], which exam-
ined the efficacy and safety of sonidegib in patients with
laBCC and mBCC.17,18 At the 6-month analysis, treatment with
sonidegib 200 mg daily demonstrated objective response rates
(ORRs) by central review of 43% in patients with laBCC and
15% in patients with mBCC.17 Subsequent analyses at 12, 18
and 30 months demonstrated sustained efficacy, with ORRs by
central review of 56–58% in laBCC and 8% in mBCC.19,20
Here we report results from the final 42-month analysis of the
BOLT study, representing the longest follow-up data available
from a clinical trial evaluating an HPI.
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Patients and methods
Study design
This was a randomized, double-blind, adaptive phase II clini-
cal study conducted in 58 centres across 12 countries, whose
design has been previously reported in detail17 and is summa-
rized in Figure 1. The study adhered to the ethical principles
of the Declaration of Helsinki, and an independent ethics
committee or institutional review board for each centre
approved the study protocol and all amendments. All patients
provided informed consent before undergoing any study-
specific procedures.
Patients age 18 years or older were eligible to enrol if they
had a histologically confirmed diagnosis of laBCC not amen-
able to radiation therapy, curative surgery or other local thera-
pies, or a histologically confirmed diagnosis of mBCC. A
World Health Organization performance status ≤ 2 was
required for enrolment. Exclusion criteria included major sur-
gery within 4 weeks of initiation of study medication, previ-
ous treatment with systemic sonidegib or other HPIs, or other
antineoplastic therapy concurrently or within 4 weeks of start-
ing study treatment. Any toxicity from prior therapy could
not exceed grade 1.
Enrolled patients were randomized in a 1 : 2 ratio to
receive sonidegib 200 mg or 800 mg once daily, approxi-
mately 2 h after a light breakfast and without any food intake
for 1 h after study drug administration. Randomization was
stratified according to disease stage (laBCC or mBCC), histo-
logical subtype (aggressive or nonaggressive) for patients with
laBCC, and geographical region. BCCs with mixed histological
features were assigned a subtype according to their most
aggressive component. Patients continued to receive study
treatment until disease progression, unacceptable toxicity,
death, study termination or withdrawal of consent.
Patients, investigators and site staff were masked to dose
allocations from randomization until the primary analysis.
Masking was maintained through identical packaging, label-
ling, appearance, odour and dosing schedules for both doses
of sonidegib.
Assessments
The primary end point was the ORR by central review, evalu-
ated using Response Evaluation Criteria in Solid Tumors
(RECIST) version 11 for patients with mBCC and modified
RECIST (mRECIST) for patients with laBCC. Standard RECIST
criteria are inadequate for evaluation of laBCC tumour
response, especially in the event of post-treatment morpholog-
ical changes, such as ulceration, cyst formation, and scarifica-
tion or fibrosis formation. Thus mRECIST was developed to
capture laBCC tumour response adequately using magnetic res-
onance imaging, colour photography and histology of multi-
ple biopsy samples.17 For patients with mBCC, evaluation was
Fig 1. Design of the BOLT study – Basal Cell Carcinoma Outcomes with LDE225 (sonidegib) Treatment. aPatients previously treated with
sonidegib or other hedgehog pathway inhibitors were excluded. bStratification was based on stage, disease histology for patients with laBCC
(nonaggressive vs. aggressive) and geographical region. cTreatment was continued until disease progression, unacceptable toxicity, death, study
termination or withdrawal of consent. AE, adverse event; BCC, basal cell carcinoma; CR, complete response; DOR, duration of response; laBCC,
locally advanced BCC; mBCC, metastatic BCC; mRECIST, modified Response Evaluation Criteria in Solid Tumors; ORR, objective response rate; OS,
overall survival; PFS, progression-free survival; Q8W, every 8 weeks; Q12W, every 12 weeks; TTR, time to tumour response.
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performed using computed tomography or magnetic reso-
nance imaging scans, as well as colour clinical photography
where appropriate. Tumour assessments were performed at
baseline (≤ 21 days prior to start of study treatment); at weeks
5, 9 and 17; then subsequently every 8 weeks during the first
year and every 12 weeks during the second year ( 3 days
for all postbaseline visits).
Key secondary efficacy end points were complete response
rate and duration of response (DOR) per central review. Other
secondary efficacy end points included ORR and DOR per
local investigator review, progression-free survival and time to
tumour response per central and investigator review, and
overall survival.
Key safety assessments included adverse events (AEs), which
were monitored throughout the study, reported using Medical
Dictionary for Regulatory Activities version 190, and graded
for toxicity using Common Terminology Criteria for Adverse
Events version 403. Additional safety assessments included
regular monitoring of haematology, serum chemistry and elec-
trocardiograms, and routine monitoring of vital signs and
physical condition. Creatine kinase (CK) was measured prior
to starting treatment or within 72 h of the first dose, as well
as every week during the first 2 months, and every 4 weeks
thereafter while on study treatment.
Statistical analyses
The intent-to-treat population included all randomized patients
and was used for all efficacy assessments. The safety popula-
tion included all patients who received at least one dose of
study drug and was used for all safety assessments.
Point estimates and 95% confidence interval (CI) were calcu-
lated for ORRs and complete response rate. An observed ORR by
central review of 30% or higher in either study arm was
required for the study to meet its primary end point, and a
lower 95% CI limit of 20% or higher was considered clinically
meaningful. DOR, progression-free survival and overall survival
were estimated using Kaplan–Meier methodology. Progression-
free survival and overall survival (where estimable) also were
summarized using the median and 95% CI. Time to tumour
response was summarized using mean, median and SD. Disease
control rate (DCR) was calculated as the sum of complete
response, partial response and stable disease rates.
Results
Patient disposition, demographics and baseline
characteristics
The study enrolled 230 patients, with 79 randomized to sonide-
gib 200 mg and 151 randomized to sonidegib 800 mg. The
intent-to-treat population included 194 patients with laBCC (66
receiving 200 mg, 128 receiving 800 mg) and 36 with mBCC
(13 receiving 200 mg, 23 receiving 800 mg). At the time of
study completion, 11 patients (48%) remained on study treat-
ment: six (8%) and five (33%) in the 200-mg and 800-mg
groups, respectively (Fig. 2). The most common reasons for
discontinuation were AEs, seen in 23 (29%) and 57 (377%)
patients, and progressive disease, seen in 29 (37%) and 24
(159%) patients in the 200-mg and 800-mg groups, respec-
tively. Patient demographics and baseline disease characteristics
were as previously summarized.17 Briefly, the median ages were
67 and 65 years for the 200-mg and 800-mg groups, respec-
tively; patients were predominantly male (61% and 636% for
the 200-mg and 800-mg groups, respectively); and patients
mostly had Eastern Cooperative Oncology Group performance
statuses of 0 (63% and 629% in the 200-mg and 800-mg
groups, respectively) (Table S1; see Supporting Information).
Efficacy outcomes per central review
The study continued to meet its primary end point, and the pre-
viously observed clinically relevant ORRs per central review for
both the 200-mg and 800-mg treatment arms were sustained at
42 months (Table 1 and Fig. 3). The ORRs per central review
for laBCC and mBCC combined were 48% (95% CI 37–60) and
417% (95% CI 338–500) for the 200-mg and 800-mg
groups, respectively. Higher ORRs (95% CI) were observed for
patients with laBCC [56% (43–68) and 461% (372–551) for
the 200-mg and 800-mg groups, respectively] than for patients
with mBCC [8% (02–36) and 17% (5–39) for the 200-mg
and 800-mg groups, respectively].
For the approved 200-mg dose, the DCR exceeded 90% both
in patients with laBCC and in those with mBCC (91% and 92%,
respectively). For the 800-mg dose, the DCR was 820% in
patients with laBCC and 91% in patients with mBCC.
The median DOR for responders to the 200-mg dose with
laBCC was 261 months (95% CI not estimable; Table 1 and
Fig. 4). Responses lasting 6 months or longer were seen in 23
of 37 responders with laBCC receiving sonidegib 200 mg
(Fig. 5). There was one long-term responder with mBCC in
the 200-mg group, whose DOR was 240 months (Fig. 4).
For the 800-mg arm, the median DOR was 233 months
(95% CI 122–296) in patients with laBCC. For patients with
mBCC, the median DOR in the 800-mg arm was not estimable
due to censoring of three of four responders.
Safety
The median durations of exposure to sonidegib were 110
months and 66 months for the 200-mg and 800-mg arms,
respectively. Overall, 54 (68%), 34 (43%) and 19 (24%)
patients were exposed to sonidegib 200 mg for ≥ 8, ≥ 12 and
≥ 20 months, respectively, whereas 65 (433%), 46 (307%)
and 23 (153%) patients were exposed to sonidegib 800 mg
for ≥ 8, ≥ 12 and ≥ 20 months, respectively.
Most AEs were manageable and reversible with dose inter-
ruptions or reductions. AEs in the 200-mg group were pri-
marily grade 1 or 2, with grade 3–4 AEs reported in 34
(43%) and 96 (640%) patients in the sonidegib 200-mg and
800-mg groups, respectively. Grade 3–4 AEs related to treat-
ment were reported in 25 (32%) and 65 (433%) patients
© 2019 The Authors. British Journal of Dermatology
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receiving sonidegib 200 mg and 800 mg, respectively. Grade
3–4 AEs led to discontinuation in 11 (14%) and 22 (147%)
patients receiving sonidegib 200 mg and 800 mg, respec-
tively. Serious AEs related to treatment were reported in four
(5%) and 26 (173%) patients receiving sonidegib 200 mg
and 800 mg, respectively. One (1%) and seven (47%) deaths
occurred within 30 days of study treatment for the 200-mg
and 800-mg groups, respectively; none were suspected to be
related to the study drug. The incidence of AEs in the
approved 200-mg group was similar to that observed in previ-
ous BOLT analyses (Table 2).
Overall, the most common AE by preferred term was mus-
cle spasms, reported in 43 (54%) and 104 (693%) patients
in the 200-mg and 800-mg groups, respectively (Fig. 6).
Alopecia was grade ≤ 2, reported in 39 (49%) and 87
(580%) patients receiving sonidegib 200 mg and 800 mg,
Fig 2. Patient disposition. aOne patient randomized to sonidegib 800 mg did not receive treatment. ITT, intent to treat.
Table 1 Efficacy outcomes per central review at 42 months
laBCC mBCC
200 mg (n = 66) 800 mg (n = 128) 200 mg (n = 13) 800 mg (n = 23)
ORR, % (95% CI) 56 (43–68) 461 (372–551) 8 (02–36) 17 (5–39)
CR, % (95%, CI) 5 (09–13) 16 (02–55) 0 (0–25) 0 (0–15)
DCR, % 91 820 92 91
DOR, median, months (95% CI) 261 (NE) 233 (122–296) 240 (NE) NE (NE)
PFS, median, months (95% CI) 221 (NE) 249 (192–334) 131 (56–331) 111 (73–166)
TTR, median, months (95% CI) 40 (38–56) 38 (37–55) 92 (NE) 10 (10–21)
The results are for the intent-to-treat population. BCC, basal cell carcinoma; CI, confidence interval; CR, complete response; DCR, disease
control rate; DOR, duration of response; laBCC, locally advanced BCC; mBCC, metastatic BCC; NE, not estimable; ORR, objective response
rate; PFS, progression-free survival; TTR, time to tumour response.
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respectively. The most common grade 3–4 AEs were elevated
CK and elevated lipase (five patients, 6% each) in the 200-mg
group, and elevated CK (20 patients, 133%) in the 800-mg
group. The most common serious AEs were pneumonia (two
patients, 3%) and elevated CK (six patients, 40%) in the 200-
mg and 800-mg groups, respectively.
In the 200-mg arm, the AEs that most frequently led to
treatment discontinuation were muscle spasms (four patients,
5%); asthenia, dysgeusia and nausea (three patients, 4% each);
and fatigue, weight loss and decreased appetite (two patients,
3% each). The AEs that most frequently led to discontinuation
in the 800-mg arm included muscle spasms (12 patients,
80%), alopecia and weight loss (nine patients, 60% each),
decreased appetite and dysgeusia (seven patients, 47% each),
nausea (six patients, 40%), fatigue (four patients, 27%),
dehydration and elevated CK (three patients, 20% each).
The most common AEs necessitating dose interruption in
the 200-mg arm included elevated CK, nausea and vomiting
(five patients, 6% each); diarrhoea and elevated lipase (four
patients, 5% each); and dysgeusia, fatigue and urinary tract
infection (three patients, 4% each). In the 800-mg arm, the
most common AEs necessitating dose interruption or reduc-
tion included muscle spasms (28 patients, 187%), nausea (19
patients, 127%), elevated CK (18 patients, 120%) and dys-
geusia and vomiting (12 patients, 80% each).
Discussion
In this final 42-month analysis of the primary efficacy and
safety results of the BOLT study, the clinical efficacy of sonide-
gib in patients with advanced BCC remained robust and con-
sistent with earlier analyses. Sonidegib demonstrated sustained
Fig 3. Objective response rates by central review across all BOLT (Basal Cell Carcinoma Outcomes with LDE225 Treatment) analyses in patients
receiving sonidegib 200 mg daily.17,19,20 Results are for the intent-to-treat population. BCC, basal cell carcinoma; laBCC, locally advanced BCC;
mBCC, metastatic BCC; ORR, objective response rate.
Fig 4. Kaplan–Meier plots of duration of response per central review in patients receiving sonidegib 200 mg daily (responders only). BCC, basal
cell carcinoma; laBCC, locally advanced BCC; mBCC, metastatic BCC; mo, months.
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clinically relevant ORRs in laBCC per central review for both
the 200-mg and 800-mg daily arms. Compared with results
from the primary analysis at 6 months, the ORR for patients
with laBCC was higher and similar to analyses performed at
12, 18 and 30 months (Fig. 3).17,19,20 Sustained response was
confirmed, with a median DOR exceeding 2 years. ORR values
were higher for patients with laBCC compared with mBCC,
potentially due to the locations of the metastatic lesions
(which could pose a challenge to accurate response assess-
ment), the heterogeneity and aggressiveness of metastatic dis-
ease, and the extent of tumour burden. Of note, the DCR
exceeded 90% in the 200-mg group for both the laBCC and
mBCC patient cohorts, indicative of treatment benefit in laBCC
as well as mBCC.
The primary reasons for treatment discontinuation were
consistent with previous analyses.17,19,20 The proportion of
patients who discontinued study treatment because of AEs or
patient’s decision was higher in the 800-mg group than in the
200-mg group, whereas discontinuations due to disease pro-
gression were more frequent in the 200-mg group. This could
potentially be attributed to patients in the 200-mg group
being more likely to remain on treatment for longer periods
until the time of disease progression.
Reported AEs were consistent with the known safety profile
of sonidegib, with no new or late-onset safety concerns
emerging at 42 months. The safety and tolerability profiles of
sonidegib 200 mg continued to be more favourable than those
for sonidegib 800 mg, with lower overall incidences in each
AE category. AEs in the 200-mg group continued to be pri-
marily grade 1 or 2, and most AEs were manageable and
reversible with dose interruptions, with no overall impact on
efficacy.
Vismodegib (Erivedge, Genentech, San Francisco, CA), an
HPI, is approved for the treatment of adults with mBCC or
with laBCC that has recurred following surgery, or patients
who are not candidates for surgery or radiation.21 In the phase
II, single-arm ERIVANCE BCC study, 71 patients with laBCC
and 33 patients with mBCC were enrolled to receive 150 mg
vismodegib once daily.22,23 Final analysis at 39 months
reported ORRs by investigator review of 60% (95% CI 47–72)
Fig 5. Duration of response by central review in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg. Results are for
the intent-to-treat population. CI, confidence interval.
Table 2 Adverse events reported with sonidegib 200 mg across all BOLT analyses (n = 79)
6 months17 12 months19 18 months20 30 months20 42 months
All AEs 75 (95) 77 (98) 77 (98) 77 (98) 77 (98)
Grade 3–4 AEs 24 (30) 30 (38) 31 (39) 34 (43) 34 (43)
All treatment-related AEs 68 (86) 70 (89) 70 (89) 70 (89) 70 (89)
Grade 3–4 AEs 18 (23) 22 (28) 23 (29) 24 (30) 25 (32)
SAEs 11 (14) 13 (17) 14 (18) 16 (20) 16 (20)
Treatment-related SAEs 3 (4) 2 (3) 2 (3) 3 (4) 4 (5)
AEs leading to discontinuation 17 (22) 22 (28) 24 (30) 24 (30) 24 (30)
AEs requiring dose interruption and/or reduction 25 (32) 30 (38) 31 (39) 34 (43) 34 (43)
The data are presented as n (%). Results are for the safety population. AE, adverse event; BOLT, Basal Cell Carcinoma Outcomes with LDE225
(sonidegib) Treatment; SAE, serious AE.
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and 49% (95% CI 31–66) in laBCC and mBCC, respectively.22
The most common AEs (percentage of patients) for the entire
duration of the study included muscle spasms (71%), alopecia
(66%) and dysgeusia (56%).22 Overall, 21% and 28% of
patients discontinued the study due to AEs and disease progres-
sion, respectively.22 The single-arm, open-label multicentre
STEVIE trial, which evaluated vismodegib 150 mg once daily
in 1215 patients with laBCC or mBCC for a median treatment
duration of 86 months (range 0–44), demonstrated similar
safety results to ERIVANCE and the present study.24
Despite the demonstrated efficacy of sonidegib, study limi-
tations include the small sample size of patients with mBCC,
with 13 and 23 patients in the 200-mg and 800-mg arms,
respectively. Together with the low number of responders in
the mBCC cohort this made the estimation of DOR challenging.
Additionally, the efficacy of sonidegib in patients with recurrent
disease following prior therapy with an HPI is unknown, as
these patients were excluded from the study.20 Another limita-
tion is the tendency of patients with advanced BCC receiving an
HPI to discontinue treatment due to low-grade AEs that cause
significant discomfort.19 Real-world treatment plans with soni-
degib should include management of AEs associated with HPI
therapy, as well as patient education and intermittent therapy,
which may also facilitate increased treatment duration, and
therefore improve patient benefit. Results from the phase II
MIKIE trial evaluating two intermittent dosing schedules of
vismodegib in 229 patients with multiple BCCs support the fea-
sibility of such therapeutic plans in this patient population.25
Overall, the 42-month analysis of BOLT confirmed the dur-
able efficacy of sonidegib for the management of laBCC and
mBCC, with the approved 200-mg dose continuing to demon-
strate a better benefit-to-risk profile than the 800-mg dose.
No new safety concerns were discovered. Sonidegib continues
to represent a viable treatment option for patients with
advanced BCC.
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